- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04311567
Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease (PULMORA)
Effects of Tofacitinib vs Methotrexate on Clinical and Molecular Disease Activity Markers in Joints and Lungs in Early Rheumatoid Arthritis (PULMORA) - A Randomized, Controlled, Open-label, Assessor-blinded, Phase IV Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Study objectives:
Primary objective: Effects of tofacitinib compared to that of methotrexate on interstitial pulmonary abnormalities at 24 weeks.
Secondary objectives: Effects of tofacitinib compared to that of methotrexate on pulmonary abnormalities and function, RA disease activity and remission rates and patient reported outcome measures at different time points. Frequency of adverse events.
Exploratory objectives: Effects of tofacitinib compared to that of methotrexate on cellular and molecular activity profiles of clinical samples from joints and lungs.
Study design:
A randomized, actively controlled, open-label, assessor-blinded, multicenter 48 weeks phase IV trial. The study design includes an optional sub-study collecting tissue samples using ultrasound-guided synovial biopsies, bronchoalveolar lavage and Particles in Exhaled Air (PExA).
Study population and intervention:
Patients with early untreated RA with active and seropositive disease will be eligible for screening and the performance of high-resolution computed tomography (HRCT). Subjects with pulmonary abnormalities suggestive of RA-ILD will be randomized (1:1) to tofacitinib 5 mg BID (group 1) or standard-of-care methotrexate 20 mg weekly (group 2) for 48 weeks. All patients receive prednisone with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib+methotrexate (group 3). Intra-articular injections of cortisone will be allowed during the study.
145 subjects will be included and screened (part 1), and approximately 48 subjects will be randomized to active treatment (part 2).
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Study coordinator
- Phone Number: +46-31-3428639
- Email: marie-louise.andersson@vgregion.se
Study Contact Backup
- Name: Eva Klingberg, MD PhD
- Phone Number: +46-31-3427745
- Email: eva.klingberg@vgregion.se
Study Locations
-
-
-
Stockholm, Sweden, 17176
- Not yet recruiting
- Karolinska University Hospital, Department of Rheumatology
-
Contact:
- Anca I Catrina, MD PhD
- Email: anca.catrina@ki.se
-
-
Skåne
-
Lund, Skåne, Sweden, 20502
- Not yet recruiting
- Skåne University Hospital, Department of Rheumatology
-
Contact:
- Meliha C Kapetanovic, MD PhD
- Email: meliha.c_kapetanovic@med.lu.se
-
-
Västra Götaland
-
Göteborg, Västra Götaland, Sweden, 41345
- Recruiting
- Clinical Rheumatology Research Center, The Sahlgrenska University Hospital
-
Contact:
- Study coordinator
- Phone Number: +46-31-3428639
- Email: marie-louise.andersson@vgregion.se
-
Contact:
- Anna-Karin H Ekwall, MD MSc PhD
- Phone Number: +46-3429360
- Email: anna-karin.ekwall@vgregion.se
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of seropositive (i.e., presence of RF and/or anti-CCP antibodies) rheumatoid arthritis (RA) according to the ACR/EULAR 2010 criteria within 24 months.
- No previous treatment with disease modifying anti-rheumatic drugs (DMARDs). History of prednisone use is allowed but should have been discontinued 2 weeks before baseline measurement.
- Active disease with ≥2 painful and ≥2 swollen joints in 66/68 joints and CRP ≥2.0 mg/L
- Aged 18-80 years
- The subject has given written consent to participate in the study.
Exclusion Criteria:
- Current active inflammatory joint disease other than RA.
- Significant and/or uncontrolled cardiac, pulmonary disease, nervous system, renal, hepatic, endocrine or gastrointestinal disorders or severe RA which in the investigator's opinion would preclude patient participation.
- Malignancy within the past 5 years, except for successfully treated cervical carcinoma in situ, basal cell and squamous cell carcinoma of the skin, with no evidence of recurrence or metastatic disease for at least 3 years.
- Primary or secondary immunodeficiency (history of, or currently active), including known history of HIV infection.
Pregnant or lactating women.
For subjects in part II the following exclusion criteria also apply:
- Women of childbearing potential not willing or able to use highly effective methods of birth control per ICH M3 (R2) for 28 days prior and 3 months after end of study.
- Active infection (excluding fungal infections of nail beds) requiring i.v. anti-infectives within 4 weeks, or oral anti-infectives within 2 weeks prior to baseline.
- Positive tests for hepatitis B (HBsAg or HBV DNA),hepatitis C serology or SARS-CoV2
- History of herpes zoster infection during last 10 years.
- History or risk of venous thromboembolism or diverticulitis.
- Positive tuberculosis history and/or positive Quantiferon test.
- Hemoglobin <90 g/L.
- Absolute neutrophil count < 1500 cells/uL.
- ASAT or ALAT >2.0 times the upper limit of normal.
- High or very high risk (≥ 5%) of cardiovascular death within 10 years by SCOREx1,5.
- Multiple incidental solid/subsolid lung nodules of size ≥6 mm, single incidental solid lung nodules ≥8 mm.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tofacitinib
Oral tablet tofacitinib 5 mg BID for 48 weeks
|
Open-label tofacitinib for 48 weeks.
All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks.
Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
Other Names:
|
Active Comparator: Methotrexate
Oral tablet methotrexate 2.5 mg: 8 tablets in one dose (=20 mg) once weekly for 48 weeks
|
Open-label methotrexate for 48 weeks.
All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks.
Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in total interstitial disease score of pulmonary abnormalities by HRCT
Time Frame: Baseline and 24 weeks
|
Total interstitial disease score will be calculated as the mean of six (anatomical levels) interstitial disease scores.
Each level's interstitial disease score will be calculated as the sum of the extent of five different parenchymal patterns (Ground glass, reticulations, honey-combing, consolidations and emphysema) measured as percentage of pattern area to total lung area at a specified anatomical level.
|
Baseline and 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in extent of parenchymal lung disease by HRCT pattern
Time Frame: Baseline and 24 weeks
|
The extent of the separate parenchymal pattern (Ground glass/reticulations/honey-combing/consolidations/emphysema) by HRCT measured as percentage of pattern area to total lung area at six different anatomical level.
|
Baseline and 24 weeks
|
Change in extent of parenchymal lung disease by HRCT pattern
Time Frame: Baseline and 48 weeks
|
The extent of the separate parenchymal pattern (Ground glass/reticulations/honey-combing/consolidations/emphysema) by HRCT measured as percentage of pattern area to total lung area at six different anatomical level.
|
Baseline and 48 weeks
|
Change in Forced Vital Capacity (FVC)
Time Frame: Baseline and 24 weeks
|
FVC will be measured by spirometry.
The proportion of patients with FVC 24wks ≤ FVC baseline will also be calculated.
|
Baseline and 24 weeks
|
Change in Diffusion Capacity of Carbon Monoxide (DLCO)
Time Frame: Baseline and 24 weeks
|
DLCO will be measured according to standard protocol and corrected for haemoglobulin level. Diffusion capacity divided by alveolar volume (DLCO/VA) will also be calculated. |
Baseline and 24 weeks
|
Change in walking distance (meters)
Time Frame: Baseline and 24 weeks
|
6-minutes walking test Diffusion capacity divided by alveolar volume (DLCO/VA) will also be calculated.
|
Baseline and 24 weeks
|
Change in blood oxygen saturation (SpO2) after 6-minutes walking
Time Frame: Baseline and 24 weeks
|
6-minutes walking test with pulse oximetry recording Diffusion capacity divided by alveolar volume (DLCO/VA) will also be calculated.
|
Baseline and 24 weeks
|
Patient reported outcome of breathing and airway symptoms
Time Frame: baseline, 24 and 48 weeks
|
Patient reported outcomes of breathing and airway symptoms will be evaluated using Saint George's Respiratory Questionnaire.
|
baseline, 24 and 48 weeks
|
Disease activity score of rheumatoid arthritis (DAS28-CRP)
Time Frame: baseline, 12, 24 and 48 weeks
|
DAS28-CRP will be calculated as follows: 0.56*√(TJC28) +0.28*√(SJC28)+0.014*PaGH+0.36*ln(CRP+1)+0.96. TJC = number of tender joints of 28, SJC= number of swollen joints of 28, CRP=c-reactive protein level and PaGH=Patient reported global impact of disease on health on a VAS scale (0-100) |
baseline, 12, 24 and 48 weeks
|
Patient reported health assessment of physical function (HAQ index)
Time Frame: baseline, 24 and 48 weeks
|
Patient reported function assessed by a validated questionnaire HAQ = health assessment questionnaire.
The assessment gives a value/index between 0 - 3.0.
|
baseline, 24 and 48 weeks
|
Proportion of patients in rheumatoid arthritis DAS remission
Time Frame: 24 and 48 weeks
|
DAS28 remission is defined as DAS28<2.6.
|
24 and 48 weeks
|
Frequency of adverse events (AE)
Time Frame: baseline, 24 and 48 weeks
|
Number of AE per category and serious AE will be calculated for the different treatment groups
|
baseline, 24 and 48 weeks
|
Patient reported global disease activity
Time Frame: baseline, 12, 24 and 48 weeks
|
Patient reported global impact of disease on health on a VAS scale (0-100 mm)
|
baseline, 12, 24 and 48 weeks
|
Proportion of patients in rheumatoid arthritis ACR-EULAR Boolean remission
Time Frame: 24 and 48 weeks
|
Boolean RA remission is defined as: SJC, TJC, PaGH and CRP, all ≤1.
TJC = number of tender joints of 28, SJC= number of swollen joints of 28 and PaGH=Patient reported global impact of disease on health on a VAS scale (0-10)
|
24 and 48 weeks
|
Clinical disease activity score of rheumatoid arthritis (CDAI)
Time Frame: baseline, 12, 24 and 48 weeks
|
Clinical disease activity score of rheumatoid arthritis (CDAI) is calculated as follows: SJC + TJC + PaGH + PhGH. TJC = number of tender joints of 28, SJC= number of swollen joints of 28, PaGH=Patient reported global impact of disease on health on a VAS scale (0-10) and PhGH=physician assessment of global impact of disease on health of patient on a VAS scale (0-10). CDAI ranges from 0 - 76. |
baseline, 12, 24 and 48 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cellular activity profile of clinical samples
Time Frame: baseline and 24 weeks
|
Exploratory sub-study: Frequencies (% of total cell populations) of subtypes of immune- and stroma cells (defined by a core set of cell surface markers) isolated from synovial biopsies and broncho-alveolar lavage samples and evaluated by flowcytometry
|
baseline and 24 weeks
|
Change in molecular activity profile of clinical samples
Time Frame: Baseline and 24 weeks
|
Exploratory sub-study: Gene expression of bulk tissue and sorted cells of synovial biopsies and broncho-alveolar lavage samples by RNA sequencing. Levels of cytokines (IL-1β, IFN-α2, IFN-γ, TNF-α, IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, and IL-33), chemokines (CCL2, CCL3, CCL4, CCL5, CCL11, CCL17, CCL20, CXCL1, CXCL5, CXCL8, CXCL9, CXCL10, CXCL11) and growth factors (GM-CSF, PDGF and TGFbeta1) of synovial fluid, blood and broncho-alveolar lavage will be determined by bead-based immunoassay. Clinical fluid droplet samples containing lipids and proteins from small airways will be collected on a membrane using a novel non-invasive method - Particles in Exhaled Air (PExA) and analyzed using mass spectrometry. |
Baseline and 24 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Anna-Karin H Ekwall, MD MSc PhD, The Sahlgrenska University Hospital and University of Gothenburg
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Lung Diseases
- Disease
- Lung Diseases, Interstitial
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Protein Kinase Inhibitors
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
- Tofacitinib
Other Study ID Numbers
- EudraCT 2019-004179-38
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on Tofacitinib
-
PfizerCompletedAnkylosing SpondylitisKorea, Republic of, United States, Spain, Taiwan, Canada, Czech Republic, Poland, Hungary, Germany, Russian Federation
-
PfizerCompleted
-
PfizerCompletedPlaque PsoriasisUnited States
-
PfizerCompleted
-
Nanfang Hospital of Southern Medical UniversityJiangsu Simcere Pharmaceutical Co., Ltd.Not yet recruitingRheumatoid Arthritis
-
PfizerCompleted
-
PfizerCompletedJuvenile Idiopathic ArthritisUnited States, Spain, Turkey, Canada, Australia, Israel, United Kingdom, Argentina, Brazil, Poland, Mexico, Belgium, Russian Federation, Ukraine
-
Stanford UniversityNational Institutes of Health (NIH)RecruitingDiaphragm InjuryUnited States